Objective. To evaluate the therapeutic efficacy of intravesical pentosanpolysulfate (PPS) in interstitial cystitis (IC) patients.
INTRODUCTION
Interstitial Cystitis (IC) includes a large group of patients with bladder pain, irritative voiding symptoms (urgency, frequency, nocturia and dysuria) and sterile urine. With little certain about its pathology and etiology a committee convened by the National Institutes of Health has arbitrarily proposed a set of characteristics to define the disease 1 . Despite the exponentional growth in clinical and basic research, no effective standard treatment is available. Small series have reported favourable results with a large variety of drugs, but placebo-controlled studies are rare.
Surface glycosaminoglycans, the 'mucus' lining of the bladder, have been identified as the defence mechanism coating and protecting the transitional cell surface 2, 3 . A current etiologic hypothesis of IC is a defect in the epithelial barrier of the bladder, which allows normal or abnormal substances in the urine to gain inappropriate access to the deeper layers of the bladder wall, initiating a circle of irritation and recruitment of immune cells and immune-mediated responses.
Experimentally sodium pentosanpolysulfate (PPS), a heparin analogue, has been shown to reinforce the glycosaminoglycans and reduce transitional cell injury 4 . These results and theories formed the rationale to use PPS for the treatment of interstitial cystitis. Different success rates were reported with oral PPS 4 -9 . In a preliminary pilot study at our centre, pentosanpolysulfate was applied intravesically (300 mg in 50 ml saline 0.9%, twice in a week) instead of orally. Long-term symptomatic and objective remission was observed in four out of the six patients, and tolerance was excellent 10 .
Based on these results, a placebo-controlled prospective, double-blind study was designed to evaluate the therapeutic efficacy of intravesical pentosanpolysulfate compared to placebo in IC patients.
PATIENTS AND METHODS
This study was conducted in a double-blind manner, and a placebo control group was used as a comparison. The study was unicentered and approved by the Human Investigation Committee at our hospital. Patients were informed verbally and in written, and informed consent was obtained from each of them. The requested number of patients for each protocol was estimated before the trial on the basis of the results of the preliminary pilot-study; the outcome was 10. The treatment period in both protocols was 3 months.
Patients were recruited from the northern part of the Netherlands, with an estimated population of 1.7 x 10 6 ; our university hospital serving as a primary and referral hospital. Pentosanpolysulfate was ordered commercially (Bayer a.g., München-Germany) as injection fluid vials (100 mg/ml). The hospital pharmacy converted them into sterile bladder instillations of 300 mg pentosanpolysulfate in 50 cc Urotainer (0.9% sodium chloride). The solution was colourless, without odour and remained stable for a minimum of 6 weeks, stored in a refrigerator. All the patients applied twice weekly intravesical pentosanpolysulfate. The first instillations took place at the hospital and treatment was continued at home by self-catheterisation, after instructions, or with the help of a district nurse. Instillations were collected every 3 weeks at the hospital.
Efficacy evaluation was based on subjective and objective parameters. An overall impression of the symptom-status was recorded at the end of three months. The subjective improvement was evaluated using a visual analoque scale scoring 1 to 5 points. Treatment was considered to be successful if there was a 1-point or greater reduction on the severity scale.
Objective parameters. The 24-hour frequency, the average voiding volume, the maximum volume voided and the nocturia were recorded from a 48-hour voiding chart completed by the patient before treatment started and at 6-weekly intervals. A cystometrogram was performed before installment of therapy and after 3 months, using a flow rate of 20 ml/min. Urodynamic capacity was defined as the voided volume after maximum filling increased with the residual bladder volume. In this way, differences in diuresis during the filling phase were eliminated. Normal desire volume was defined as the feeling that leads the patient to pass urine at the next convenient moment. Subjective and objective parameters in the two groups were comparable at the start of the study.
Patients retained the pentosanpolysulfate intravesically for as long as urge and pain made it possible. Retention varied from 30 to almost 180 minutes, without irritative side-effects. Nineteen of the patients managed with self-catheterisation, while one was assisted by a district nurse. Urine cultures remained negative. The main expected side-effect, hematuria, attributed to the heparin-like qualities of the drug, was reported incidentally after instillation. The hematuria always disappeared spontaneously within 2 days, never necessitating a medical consult.
After three months of treatment, an overall subjective improvement in symptoms was reported by four patients (44%) in the PPS group (n=9), by two (20%) in the placebo group (n=10). This difference was not statistically significant. All other patients reported unchanged symptoms. Table 1 shows the mean values of the objective parameters. Except for the urodynamic capacity other, marginal, differences were not statistically significant. A decrease was noted in the average voiding volume in the PPS-after-placebo group caused by a dramatic decrease in one patient who remained symptomatically unchanged. A statistically significant increase (p=0.047, Student t-test, one-tail probe) in the urodynamic capacity was recorded after 3 months of PPS treatment compared to the pre-trial volume. The increase (from 208 to 229 ml) in the patients receiving PPS after placebo was not statistically significant.
Following the placebo-controlled period of three months eleven (55%) patients continued PPS instillations. Four patients did not continue because they judged their symptoms acceptable while five patients preferred other conservative options. From the group of patients (n=8) who continued with PPS after 3-months-placebo six (75%) reported symptomatic improvement and mean objective parameters improved although, not statistically significant ( Table 1) . 
DISCUSSION
The primary subjective measurement used to determine effectiveness was the patient evaluation of overall improvement. In the group of patients treated with PPS, 44% experienced symptomatic relief versus 20% of the patients treated with placebo. This difference was not statistically significant. Differences between objective parameters were marginal, only functional bladder capacity showed a statistically significant increase in patients treated with PPS. Eleven (55%) patients continued PPS instillations after completion of the study protocol. One and a half year from the start of the study eight (40%) patients are still on treatment.
The treatment of IC is largely empiric because of the unknown cause of the disease. A wide variety of oral and intravesical agents are currently employed 11 . Employment of pentosanpolysulfate in the treatment of IC is based on the pathogenetic theories referred to previously. The pharmacological effect of PPS is affinity for mucosal membranes, which results in coating of the surface, particularly where the normal sulfonated glycosaminoglycan layer is missing. Furthermore, PPS inhibits inflammatory processes involving lysosomal proteases and inflammatory mediators. Because pentosanpolysulfate orally is absorbed only marginally (3-5%) from the gastro-intestinal tract, we hoped to improve its therapeutic efficacy by intravesical application. The dose we applied was similar to the daily oral prescription (300 mg) and arbitrarily instilled twice a week for a period of 3 months. The double-blind design of the study offered the option of cross-over. However, it was considered inhumane to ask patients with persistent symptoms and pain to risk another three months of only placebo treatment. Reports on oral pentosanpolysulfate have shown moderate to substantial relief of symptoms in 50% up to 80% 4, 6 . However, these were un-controlled studies. The main results and characteristics of four placebo-controlled oral PPS studies and our intravesical placebo-controlled PPS trial are shown in Table 2 5,7,8,10 . The oral studies are well compatible in respect of the number of included patients, drop-out percentage and methodology. All of them employed visual analogue scales to evaluate improvement, either subdivided in points (0-5) 7 or in percentages (0-25%-50%-75%-100% improvement) 9 and all studies included patients who failed to respond to prior conservative treatment. However, compared to the placebo-controlled studies from the USA, the European studies lack statistically significance. Our recent epidemiologic study in The Netherlands revealed that general and specific 
CONCLUSIONS
We concluded the efficacy of intravesical PPS to be slight superior to oral PPS. In addition, self-catheterisation enabled long-term treatment and fascilitated the 'self-help' capacity of IC patients.
Whether a longer, more intense course of intravesical PPS or a combination with other agents will produce better results is currently under investigation.
